Modelling the efficacy of CIK cell immunotherapy targeting MET-expressing mesothelioma cells

Le résumé fourni par la source

Mesothelioma is a highly aggressive cancer of the mesothelial lining whose incidence continues to rise, mainly due to asbestos exposure and the long latency between exposure and disease onset. Given the limited efficacy of current treatments, novel immunotherapeutic strategies are being explored, including the use of CIK immune cells engineered with a MET-specific receptor to target MET-overexpressing tumours. We combine experimental and mathematical modelling approaches to investigate the interaction dynamics between tumour and CIK cells, focusing on the influence of tumour MET expression on CIK-mediated cytotoxicity. Ex vivo data from mesothelioma and CIK cell lines are used to inform, calibrate, and validate a mathematical model that incorporates a partial integro-differential equation describing cancer cell dynamics structured by MET expression level. The model is then employed to explore tumour–CIK combinations and predict outcomes under yet-untested experimental conditions.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.